PJ

Worked in pharma for 20 years- passion for biotech stocks. Swing/day trader and investor, depending what market dictates.

[PJ @pjf949]

$IOVA 🚀 #Amtagvi #NSCLC #IOV-4001 #IOV-5001

[PJ @pjf949]

$IOVA great Q4 and corporate updates https://t.co/SyIk2E6din

[PJ @pjf949]

$IOVA Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) – IOVANCE Biotherapeutics, Inc. https://t.co/uxxVsL2aaV

[PJ @pjf949]

$AQST >11M shares traded today
#Anaphylm #AQST-108

[PJ @pjf949]

$AQST huge volume
#Anaphylm #AQST-108

[PJ @pjf949]

$AQST #Anaphylm

[PJ @pjf949]

$IOVA Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting – IOVANCE Biotherapeutics, Inc

Confirmed ORR was 65.2%, including 7 (30.4%) complete responses and 8 (34.8%) partial responses by RECIST v1.1. https://t.co/IsweG6WjZx

[PJ @pjf949]

$IOVA Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates – IOVANCE Biotherapeutics, Inc. #Amtagvi https://t.co/MFHy5Z0I2f

[PJ @pjf949]

$XFOR X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome | X4 Pharmaceuticals, Inc. #WHIM #CN https://t.co/XLKbLxceqo

[PJ @pjf949]

#AQST Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film - Aquestive Therapeutics https://t.co/iwvrt8F9cP

[PJ @pjf949]

$DAWN Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor | Day One Biopharmaceuticals, Inc. https://t.co/psakdckVw5

[PJ @pjf949]

$GLYC GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687 - GlycoMimetics, Inc.

$NVS watching 2nd generation E-selectin #SCD #VOCs

https://t.co/YF3UJvNsk4

[PJ @pjf949]

$EFTR eFFECTOR Therapeutics Announces New Positive Interim Data
mPFS = 7.4 months https://t.co/88FKD2T1JO

[NOTRELOAD AI @notreload_ai]

“Median progression free survival (mPFS) of 7.4 months in the ZFA expansion cohort evaluating zotatifin in combination with fulvestrant and abemaciclib in heavily pretreated patients with ER+ metastatic breast cancer (mBC),” $EFTR https://t.co/QANIrP0GhP

[PJ @pjf949]

$GLYC

[PJ @pjf949]

$MREO

[PJ @pjf949]

$OCUL

[PJ @pjf949]

$TGTX

[PJ @pjf949]

$CRVS

[PJ @pjf949]

$RCEL